The World Anti-Microbial Resistance Congress

The World Anti-Microbial Resistance Congress

October 24, 2018
2 min read

World Anti-Microbial Resistance Congress emphasizes global coordination efforts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Andre Singer
André Singer

The fourth annual World Anti-Microbial Resistance Congress, held in Washington, D.C., from Oct. 25 to 26, will address antibiotic research and development, diagnostics, antimicrobial stewardship and innovation.

“As the only commercially focused antimicrobial resistance (AMR) event globally, we are thrilled to bring together over 400 stakeholders to discuss strategies and commercial approaches to combat AMR,” André Singer, general manager of the World Anti-Microbial Resistance Congress, told Infectious Disease News.

In the United States, one in three antibiotics are unnecessarily prescribed, according to the CDC. Additionally, the agency says that an estimated 2 million people become ill from resistant infections each year, resulting in approximately 23,000 deaths. Worldwide, resistant infections cause around 700,000 deaths each year and, according to WHO, that number could climb to 10 million in the next 35 years.

The congress began in 2015 as a way for experts from around the world to meet and discuss strategic approaches for combating AMR. Hospitals, investors, government employees, regulators, international organizations, funding agencies and innovative solution providers will focus on the most pressing issues surrounding AMR through interactive and collaborative discussions.

At this year’s AMR Congress, 150 speakers will discuss topics ranging from preclinical, clinical and commercial pathways for antibiotic research and development to novel antimicrobial stewardship initiatives. The keynote address on the first day of the congress, given by Dan Wechsler, CEO and president of Melinta Therapeutics, will address stewardship and the development of new diagnostics and drugs to fight resistance. Another keynote address will be presented by Paul Auwaerter, MD, clinical director in the division of infectious diseases at Johns Hopkins School of Medicine and president of the Infectious Diseases Society of America, followed by roundtable discussions about fighting infections, hostcentricity and trial awareness, among other topics. On day two, the keynote speaker Larry Kerr, PhD, director of the Office of Pandemic and Emerging Threats in the HHS and the co-chair of the Transatlantic Taskforce on Antimicrobial Resistance, or TATFAR, will address the critical need for international coordination to combat resistance.

“At our fourth annual congress, we will discuss critical challenges and opportunities to advance antibiotic and diagnostics development, improve antimicrobial stewardship practice and incentivize funding and partnering to bring innovation to patients and the health care system in need,” Singer said.

Infectious Disease News will be on site in D.C. to report on the some of the presentations and discussions at the meeting. Check back regularly at for updates. – by Marley Ghizzone


CDC. CDC: 1 in 3 antibiotic prescriptions unnecessary. Accessed October 23, 2018.

CDC. Antibiotic / Antimicrobial Resistance (AR / AMR). Accessed October 23, 2018.

WHO. United Nations meeting on antimicrobial resistance. Accessed October 23, 2018.

Disclosure: Singer general manager of the World Antimicrobial Resistance Congress.